Pfizer (PFE) Fundamental Analysis: Revenue, Earnings & Valuation

3.97 / 10

Netural

Fundamental rating is Neutral with a 4.0/10 score. Positive factors include Days Sales Outstanding, Cost‑of‑Sales ratio and Profit‑to‑Market‑Value, while revenue growth YoY is negative and Asset‑to‑Market‑Value is below peers. Overall fundamentals are inadequate, suggesting selective investment.

Analysis Checks(6/10)

Total operating revenue (YoY growth rate %)

Value-1.65

Score1/3

Weight-1.66%

1M Return-0.48%

Days sales outstanding

Value67.13

Score2/3

Weight0.41%

1M Return0.11%

Accounts receivable turnover ratio

Value5.36

Score3/3

Weight-3.73%

1M Return-1.06%

Profit-MV

Value1.21

Score3/3

Weight44.79%

1M Return9.28%

PB-ROE

Value-0.38

Score2/3

Weight29.98%

1M Return7.17%

Income tax / Total profit (%)

Value-3.54

Score1/3

Weight-3.50%

1M Return-1.02%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.93

Score2/3

Weight-4.22%

1M Return-1.25%

Operating revenue (YoY growth rate %)

Value-1.65

Score1/3

Weight-1.44%

1M Return-0.42%

Cost of sales ratio (%)

Value25.67

Score3/3

Weight4.56%

1M Return1.16%

Asset-MV

Value-0.55

Score1/3

Weight34.81%

1M Return6.70%

Is PFE undervalued or overvalued?

PFE scores 3.97/10 on fundamentals and holds a Fair valuation at present. Backed by its 8.87% ROE, 12.48% net margin, 19.74 P/E ratio, 1.77 P/B ratio, and -3.52% earnings growth, these metrics solidify its Netural investment rating.